BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA Fast Track Designation
Advertisement
Aclaris Therapeutics Receives FDA Fast Track for Modzatinib
WAYNE, Pa., August 6, 2026 Aclaris Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
CORE Biomedicine Secures $21M Series A Funding
BOSTON, TOKYO and SUZHOU, July 28, 2026 CORE Biomedicine, a biotechnology company advancing lineage-based precision oncology therapeutics, has announced...
Co-Diagnostics Advances Ebola Testing Innovation Globally
SALT LAKE CITY, July 28, 2026 Co-Diagnostics, Inc. has announced two significant milestones that strengthen global preparedness against Ebola...
Dasher Neuroscience Advances YA-101 Phase 2 Trial
TAIPEI, July 28, 2026 Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical...
Advertisements
Solu Therapeutics Wins FDA Fast Track for STX-0712
BOSTON, Mass., May 27, 2026 Solu Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Armata Gains FDA Fast Track for AP-SA02 Therapy
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
FDA Grants Fast Track to Nipocalimab for Lupus Treatment
SPRING HOUSE, Pa., March 3, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) Fast Track...
Adcendo Secures FDA Fast Track for ADCE-D01 Targeting Soft Tissue Sarcoma
COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates...
Vivace Therapeutics Gains FDA Fast Track Designation for VT3989 in Mesothelioma
SAN MATEO, Calif., October 8, 2025 — Vivace Therapeutics, Inc., a biotechnology company pioneering small molecule cancer therapies that...
Advertisement
